-
A preliminary study comparing the performance of thyroid molecular tests to a deep learning algorithm in predicting malignancy in indeterminate thyroid fine needle aspiration biopsies. Thyroid (IF 6.6) Pub Date : 2023-11-27 Serge Assaad,David Dov,Christine Park,Richard Davis,Shahar Z Kovalsky,Walter T Lee,Russel R Kahmke,Daniel J Rocke,Jonathan Cohen,Ahuva Weiss-Meilik,Ricardo Henao,Lawrence Carin,Danielle Range
-
Comparative Analysis of Taxonomic and Functional Gut Microbiota Profiles in Relation to Seroconversion of Thyroid Peroxidase Antibodies in Euthyroid Participants. Thyroid (IF 6.6) Pub Date : 2023-11-27 Aline C Fenneman,Ulrika Boulund,Didier Collard,Henrike Galenkamp,Ailko Zwinderman,Bert Jan van der Born,Anne H van der Spek,Eric Fliers,Elena Rampanelli,Martin Blaser,Max Nieuwdorp
BACKGROUND Previous studies have reported gut microbiome alterations in Hashimoto's autoimmune thyroiditis (HT) patients. Yet, it is unknown whether an aberrant microbiome is present before clinical disease onset in participants susceptible to HT or whether it reflects the effects of the disease itself. Here, we report for the first time a comprehensive characterization of the taxonomic and functional
-
Evaluating ChatGPT responses on thyroid nodules for patient education. Thyroid (IF 6.6) Pub Date : 2023-11-27 Daniel J Campbell,Leonard E Estephan,Elliott Sina,Eric V Mastrolonardo,Rahul Alapati,Dev R Amin,Elizabeth Cottrill
BACKGROUND ChatGPT, an artificial intelligence (AI) chatbot, is the fastest growing consumer application in history. Given recent trends identifying increasing patient use of Internet sources for self-education, we seek to evaluate the quality of ChatGPT-generated responses for patient education on thyroid nodules. METHODS ChatGPT was queried 4 times with 30 identical questions. Queries differed by
-
Association Between Antibiotic Exposure and Thyroid Cancer: A Nationwide Cohort Study in South Korea. Thyroid (IF 6.6) Pub Date : 2023-11-27 Sun Jae Park,Minseo Kim,Seogsong Jeong,Young Jun Park,Seulggie Choi,Jooyoung Chang,Yun Hwan Oh,Sun Wook Cho,Young Joo Park,Sang Min Park
BACKGROUND Although recent studies have introduced antibiotics as a potential risk factor for thyroid cancer, further studies are necessary. We examined the association between long-term antibiotic usage and thyroid cancer risk. METHODS This nationwide cohort study investigated 9,804,481 individuals aged 20 years or older who participated in health screening (2005-2006) with follow-up ending on December
-
Molecular diagnostics and [18F]FDG-PET/CT in indeterminate thyroid nodules: complementing techniques or waste of valuable resources? Thyroid (IF 6.6) Pub Date : 2023-11-27 Elizabeth J de Koster,Hans Morreau,Gysele S Bleumink,Ilse van Engen-van Grunsven,Lioe-Fee de Geus-Oei,Thera P Links,Iris M M J Wakelkamp,Wim J G Oyen,Dennis Vriens
BACKGROUND An accurate preoperative workup of cytologically indeterminate thyroid nodules (ITN) may rule-out malignancy and avoid diagnostic surgery for benign nodules. The current study assessed the performance of molecular diagnostics (MD) and [18F]FDG-PET/CT in ITN, including their combined use, and explored whether molecular alterations drive the differences in [18F]FDG uptake among benign nodules
-
Outcomes in Maternal Graves' Disease: A Population-Based Mother-Infant Dyad Cohort Study. Thyroid (IF 6.6) Pub Date : 2023-11-27 Eyal Cohen-Sela,Avivit Brener,Orian Raviv,Michal Yackobovitch-Gavan,Shlomo Almashanu,Ronella Marom,Matan Anteby,Liran Hiersch,Yael Lebenthal
BACKGROUND Graves' disease has been associated with adverse pregnancy, labor and delivery, and neonatal outcomes. Thyroid function levels, assessed during newborn screening (NBS), can serve as indicators of the adaptation in the hypothalamic-pituitary-thyroid axis. We utilized data from the national thyroid NBS program to investigate the characteristics of the mother-infant dyad of term infants born
-
Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid (IF 6.6) Pub Date : 2023-11-27 Vivek Subbiah,Mimi I Hu,Aaron S Mansfield,Matthew H Taylor,Martin Schuler,Viola W Zhu,Julien Hadoux,Giuseppe Curigliano,Lori Wirth,Justin F Gainor,Guzman Alonso,Douglas R Adkins,Yann Godbert,Myung-Ju Ahn,Philippe A Cassier,Byoung Chul Cho,Chia-Chi Lin,Alena Zalutskaya,Teresa Barata,Peter Trask,Astrid Scalori,Walter Bordogna,Sebastian Heinzmann,Marcia Brose
BACKGROUND RET alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. We present an updated analysis with more patients and longer follow-up. METHODS Adult patients with advanced/metastatic
-
Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study. Thyroid (IF 6.6) Pub Date : 2023-11-20 Xinyang Li,Yingying Li,Lin Yan,Jing Xiao,Zhen Yang,Haoyu Jing,Mingbo Zhang,Yukun Luo
Background: The criteria for determining technical efficacy of thermal ablation for papillary thyroid carcinoma (PTC) are not clearly defined. We analyzed the involution process of the ablation zone with clear pathologic results on core-needle biopsy (CNB) to clarify the relationship between sonographic changes and pathologic findings. Methods: This retrospective cohort study included 382 patients
-
Rates of Detecting Thyroid Nodules Recommended for Biopsy with Ultrasound: Are All Indications Equal? Thyroid (IF 6.6) Pub Date : 2023-11-19 Elena Kennedy,Chad Zhang,Yazeed Qadadha,Christie Feng Cheng,Abdullah Adil,Kathy Bach,Dave Smith,Natalia Arroyo,Sara Fernandes-Taylor,Lori Gettle,Ann Marie Mayer,David O Francis,Alexander S Chiu
BACKGROUND The use of thyroid ultrasound increases yearly, adding to costs and over-detection of clinically irrelevant nodules. We investigated which indications most commonly prompt referral for thyroid ultrasound and the diagnostic utility by indication. METHODS We performed a retrospective observational cohort study of adults (≥18 years) undergoing an initial, dedicated thyroid ultrasound between
-
Re: "Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status" by Van Uytfanghe et al. Thyroid (IF 6.6) Pub Date : 2023-11-17 Stephen P Fitzgerald,Henrik Falhammar,Rudolf Hoermann
-
Efficacy of Levothyroxine Sodium Soft Gelatin Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors: An Open-Label Study. Thyroid (IF 6.6) Pub Date : 2023-11-16 Issac Sachmechi,Kathryn Jean Lucas,Larry D Stonesifer,John Fitzgerald Ansley,Paul Sack,Francesco S Celi,Claudia Scarsi,Gabriele Lanzi,Leonard Wartofsky,Kenneth D Burman
Background: Treatment with proton pump inhibitors (PPIs) and antacids affects the gastrointestinal absorption of levothyroxine sodium (LT4) tablets. Patients with hypothyroidism taking LT4 and PPIs or antacids, thus, require appropriate monitoring. The objective of this study was to determine whether a soft gelatin capsule of LT4 (Tirosint®) would obviate the effect of PPIs on LT4 absorption. The objective
-
Response to Szymczak et al. re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion". Thyroid (IF 6.6) Pub Date : 2023-11-16 Ayanthi Wijewardene,Karine Bastard,Bin Wang,Matti Gild,Catherine Luxford,Anthony Gill,Bruce Robinson,Martyn Bullock,Roderick Clifton-Bligh
-
Is Thyroid Dysfunction Associated with Unruptured Intracranial Aneurysms? A Population-Based, Nested Case-Control Study from Korea. Thyroid (IF 6.6) Pub Date : 2023-11-15 Hyeree Park,Sun Wook Cho,Sung Ho Lee,Kangmin Kim,Hyun-Seung Kang,Jeong Eun Kim,Aesun Shin,Won-Sang Cho
Background: Few risk factors for the development of intracranial aneurysms (IAs) are known. We investigated the potential role of thyroid diseases in IA development using nationwide real-world data. Methods: A nested case-control study within the National Health Insurance Service-National Sample Cohort data from 2002 to 2019 was performed. A total of 5335 patients with unruptured IA were matched by
-
Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy. Thyroid (IF 6.6) Pub Date : 2023-11-15 JaeSang Ko,Yong Joon Kim,Soo Hyun Choi,Christopher Seungkyu Lee,Jin Sook Yoon
Background: In Graves' orbitopathy (GO), localized orbital inflammation within the fixed orbit often leads to a fibrotic phenotype resulting in restrictive myopathy or refractory proptosis. However, the molecular pathways related to the transition from inflammation to fibrosis in GO are less understood. Yes-associated protein (YAP) and its homolog, transcriptional coactivator with PDZ-binding motif
-
A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease. Thyroid (IF 6.6) Pub Date : 2023-11-14 Raymond D Douglas,Emanuil Parunakian,Joseph Tolentino,Emil Malkhasyan,June Geng,Michele Sherman,Shoaib Ugradar
N/A.
-
Characterization of the thyroid cancer genomic landscape by plasma-based circulating tumor DNA next-generation sequencing. Thyroid (IF 6.6) Pub Date : 2023-11-14 Valentina D Tarasova,Jill Tsai,Jude Masannat,Juan Hernandez-Prera,Julie E Hallanger-Johnson,Colleen Veloski,Sarimar Agosto Salgado,Bryan McIver,Leylah Drusbosky,Christine H Chung
BACKGROUND The limited availability of targeted therapies in thyroid cancer (TC) has challenged conventional treatment algorithms and has established urgency for the identification of targetable genomic abnormalities. In addition to widely adopted tissue-based next-generation sequencing (NGS), plasma-based circulating tumor DNA (ctDNA) NGS is rapidly emerging as a genomic biomarker detection method
-
Health-Related Quality of Life in Patients with Low-Risk Differentiated Thyroid Cancer: A Systematic Review Examining the Extent of Thyroidectomy. Thyroid (IF 6.6) Pub Date : 2023-11-14 Kathy Bach,Palvishey Ansari,Hamayail Ansari,Nicole M Mott,Dawn M Elfenbein,Hunter Underwood,Susan C Pitt
Background: Total thyroidectomy (TT) and hemithyroidectomy (HT) are acceptable surgical options for the treatment of low-risk differentiated thyroid cancer (DTC). While previous data suggest similar disease-free and disease-specific survival regardless of initial surgical treatment, the effect of the extent of surgery on health-related quality of life (HRQOL) is less clear. This systematic review aimed
-
Modified ACR TI-RADS and Modified AI TI-RADS for Thyroid Nodules: A Multicenter Retrospective Study. Thyroid (IF 6.6) Pub Date : 2023-11-11 Xiaoxian Li,Chuan Peng,Ying Liu,Yixin Hu,Liang Yang,Yiwen Yu,Hongyan Zeng,Weijun Huang,Qian Li,Nansheng Tao,Longhui Cao,Jianhua Zhou
BACKGROUND Risk stratification systems for thyroid nodules are limited by low specificity. The fine-needle aspiration (FNA) biopsy size thresholds and stratification criteria are based on evidence from the literature and expert consensus. Our aim was to investigate the optimal FNA biopsy size thresholds in the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) and
-
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study. Thyroid (IF 6.6) Pub Date : 2023-11-07 Bin Xu,Kartik Viswanathan,Mahsa S Ahadi,Sara Ahmadi,Bayan Alzumaili,Mohamed-Amine Bani,Eric Baudin,David Blake Behrman,Marzia Capelletti,Nicole G Chau,Federico Chiarucci,Angela Chou,Roderick Clifton-Bligh,Sara Coluccelli,Dario de Biase,Antonio De Leo,Snjezana Dogan,James A Fagin,Talia L Fuchs,Anthony Robert Glover,Julien Hadoux,Ludovic Lacroix,Livia Lamartina,Daniel J Lubin,Catherine Luxford,Kelly
Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) need to be clarified. Experimental Design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data
-
Cardiac Safety and Efficacy of Combination Levothyroxine and L-Triiodothyronine in Patients with Athyreotic Hypothyroidism: Reassuring Initial Data but More Is Needed. Thyroid (IF 6.6) Pub Date : 2023-11-03 Salman Razvi
-
A Multicentre Retrospective Study of Anaplastic Thyroid Cancer in the Era of Targeted Therapy in a Public Health Care System: Canada's Experience. Thyroid (IF 6.6) Pub Date : 2023-11-01 Michael K Gupta,Ana-Maria Misariu,Nadim Saydy,Anthony C Nichols,Francisco Laxague,Antoine Eskander,Huaqi Li,Natalie Weisbrod,Jesse D Pasternak,Bahar Golbon,Elaine Jin,Stan H M van Uum,Maryse Brassard,Florence Lévesque,Nader Sadeghi,Thavakumar Subramaniam,Aleksander M Mlynarek,Gregoire Bernard Morand,Pierre H Fortier,Laurent Fradet,Sana Ghaznavi,Shamir P Chandarana,Eitan Prisman,Tareck Ayad,Apostolos
-
Comparison of Perioperative Outcomes in Patients with Graves' Disease Undergoing Total Thyroidectomy with or without Near Infrared Auto-Fluorescence Imaging. Thyroid (IF 6.6) Pub Date : 2023-10-28 Melis Uysal,Ege Akgun,Ali Gunduz Sarioglu,Eren Berber
BACKGROUND The impact of near-infrared autofluorescence (NIRAF) imaging on post-thyroidectomy hypocalcemia is controversial. As patients with Graves' disease are at increased risk, our aim was to compare postoperative parathyroid function in these patients undergoing total thyroidectomy with or without NIRAF imaging. METHODS This was a retrospective "before and after" study, comparing outcomes of patients
-
Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways. Thyroid (IF 6.6) Pub Date : 2023-10-27 Xi Xiao,Mengke Chen,Ye Sang,Junyu Xue,Ke Jiang,Yulu Chen,Luyao Zhang,Shuang Yu,Weiming Lv,Yanbing Li,Rengyun Liu,Haipeng Xiao
Background: Aberrant expression of oncogenes and/or tumor suppressor genes (TSGs) drives the tumorigenesis and development of thyroid cancer. We investigated the expression and function of a member of the activating transcription factor (ATF)/cAMP-responsive element-binding protein (CREB) transcription factor (TF) family, ATF3, in thyroid cancer. Methods: Data from 80 patients with papillary thyroid
-
Height, Autoimmune Thyroid Disease, and Thyroid Cancer: A Mendelian Randomization Study. Thyroid (IF 6.6) Pub Date : 2023-10-26 Areti Papadopoulou,Bjørn O Åsvold,Stephen Burgess,Aleksander Kuś,Marco Medici,Rosalie Sterenborg,Alexander Teumer,Panos Deloukas,Eirini Marouli
Background: Increased height has been associated with increased risk of hypothyroidism or thyroid cancer in epidemiological studies. However, the potential causal association between height and hypothyroidism or thyroid cancer has not been thoroughly explored. Autoimmune thyroid disease (AITD) mainly presents as hypothyroidism, thus we aim to evaluate the causal relationship between height as exposure
-
Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients. Thyroid (IF 6.6) Pub Date : 2023-10-23 Bernadette Biondi,Martina Pucci,Gilda Pontieri,Pietro Formisano,Roberta Esposito
Background: Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) for the treatment of hypothyroidism. Objective and Methods: We performed a randomized, double-blind placebo-controlled study to assess the effects of LT4+LT3 therapy versus LT4+placebo in a homogeneous group of athyreotic patients, without cardiovascular risk factors during long-term
-
-
Fracture Incidence in Graves' Disease: A Population-Based Study. Thyroid (IF 6.6) Pub Date : 2023-10-19 Selwan Khamisi,Ruzan Udumyan,Gabriel Sjölin,Jan Calissendorff,Helena Filipsson Nyström,Mats Holmberg,Bengt Hallengren,Mikael Lantz,Tereza Planck,Göran Wallin,Östen Ljunggren
Background: Population-based studies have indicated an increase in bone turnover in hyperthyroidism with a subsequent decrease in bone mineral density and an increased risk of fractures, especially in postmenopausal women. However, heterogeneity between studies prevents a definitive conclusion. Graves' disease (GD) is an autoimmune disease, and it is the most common cause of hyperthyroidism. The aim
-
A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis. Thyroid (IF 6.6) Pub Date : 2023-10-19 Simone De Leo,Silvia D'Elia,Giorgio Grani,Francesco Dondi,Francesco Bertagna,Efisio Puxeddu,Silvia Morelli,Alessandro Piovesan,Alice Nervo,Maria Chiara Zatelli,Irene Gagliardi,Maria Teresa Samà,Gianluca Aimaretti,Umberto Crocetti,Michela Massa,Maurilio Deandrea,Francesca Retta,Loredana Pagano,Mattia Rossi,Erica Solaroli,Luciano Pezzullo,Maria Grazia Chiofalo,Alfredo Pontecorvi,Celestino Pio Lombardi
Background: There is some controversy on the potential relationship between autoimmune processes and clinicopathologic features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its largely retrospective nature. We examined the relationship between the presence of autoimmune thyroiditis (AT) and 1-year thyroid cancer treatment outcomes in a large multicenter
-
Thyroglobulin Antibodies in Women with Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Thyroid (IF 6.6) Pub Date : 2023-10-18 Perrine Huisman,Jesper Krogh,Claus Henrik Nielsen,Henriette Svarre Nielsen,Ulla Feldt-Rasmussen,Sofie Bliddal
Background: Thyroid autoimmunity is the most prevalent autoimmune disorder among women of reproductive age and has been suggested as a risk factor in recurrent pregnancy loss (RPL)-a condition in which couples suffer several consecutive pregnancy losses, but where a cause can be identified in less than half of the cases. Most studies have focused on thyroid peroxidase antibodies (TPOAbs), not considering
-
Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization. Thyroid (IF 6.6) Pub Date : 2023-10-17 Paul Stewardson,Markus Eszlinger,Jiahui Wu,Moosa Khalil,Adrian Box,Marco Perizzolo,Zoya Punjwani,Bjoern Ziehr,Ratna Sanyal,Douglas J Demetrick,Ralf Paschke
Background: Molecular testing for cytologically indeterminate thyroid nodules (ITNs) is often reported with incomplete data on clinical assessment and ultrasound malignancy risk (USMR) stratification. This study aimed to clinically validate the diagnostic accuracy of a novel molecular test, assess the incremental preoperative malignancy risk of other clinical factors, and measure the impacts of introducing
-
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer. Thyroid (IF 6.6) Pub Date : 2023-10-12 David Balakirouchenane,Romain Seban,Lionel Groussin,Alicja Puszkiel,Anne Ségolène Cottereau,Jerome Clerc,Michel Vidal,Francois Goldwasser,Jennifer Arrondeau,Benoît Blanchet,Olivier Huillard
Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the exposure-toxicity relationship for dose-limiting toxicity (DLT) onset in patients treated with dabrafenib and/or trametinib and investigated whether plasma exposure was associated with RAI reuptake. Methods: We conducted a retrospective
-
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports. Thyroid (IF 6.6) Pub Date : 2023-10-09 Sophie Moog,Livia Lamartina,Mohamed-Amine Bani,Abir Al Ghuzlan,Luc Friboulet,Antoine Italiano,Ludovic Lacroix,Sophie Postel Vinay,Lambros Tselikas,Frédéric Deschamps,Baptiste Bonnet,Fabiana Pani,Eric Baudin,Julien Hadoux
Background: Patients with metastatic medullary thyroid cancer (MTC) who progressed under tyrosine kinase inhibitors can benefit from an alkylating agent such as dacarbazine or temozolomide. Patient Findings: We describe two patients with metastatic MTC who developed a hypermutant phenotype after alkylating agent treatment. This phenotype was characterized by a high tumor mutational burden (TMB) and
-
Correction to: Response to Mooij and van Trotsenburg re: ''Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: A Specific Hormonal or a General Autoimmune Comorbidity'' by Medici and Soheili-Nezhad. Thyroid 2023;33(8):1002-1003; doi: 10.1089/thy.2023.0315. Thyroid (IF 6.6) Pub Date : 2023-10-05
-
The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial. Thyroid (IF 6.6) Pub Date : 2023-10-05 Mary Waterhouse,Hai Pham,Sabbir T Rahman,Catherine Baxter,Briony Duarte Romero,Bruce K Armstrong,Peter R Ebeling,Dallas R English,Gunter Hartel,Jolieke C van der Pols,Alison J Venn,Penelope M Webb,David C Whiteman,Donald S A McLeod,Rachel E Neale
Background: Hypothyroidism is common, and in iodine-sufficient areas, it is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation
-
Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer. Thyroid (IF 6.6) Pub Date : 2023-10-03 Viswanath Gunda,Chandrayee Ghosh,Jiangnan Hu,Lisa Zhang,Ya Qin Zhang,Min Shen,Electron Kebebew
Background: Anaplastic thyroid cancer (ATC) is uniformly lethal. BRAFV600E mutation is present in 45% of patients with ATC. Targeted therapy with combined BRAF and MEK inhibition in BRAFV600E-mutant ATC can be effective, but acquired resistance is common because this combination targets the same pathway. Drug matrix screening, in BRAFV600E ATC cells, of highly active compounds in combination with BRAF
-
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. Thyroid (IF 6.6) Pub Date : 2023-10-01 Arnaud Jannin,Fabiola Giudici,Christelle de la Fouchardière,Abir Al Ghuzlan,Johanna Wassermann,Cecile N Chougnet,Delphine Drui,Yann Godbert,Frédéric Ilouz,Stéphane Bardet,Sylvie Zanetta,Nathalie Roudaut,Marie Batisse Lignier,Lionel Groussin,Marc Klein,Slimane Zerdoud,Livia Lamartina,Eric Baudin,Myriam Decaussin-Petrucci,Emmanuelle Leteurtre,Francoise Borson Chazot,Christine Do Cao,Isabelle Borget,Julien
Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France. Methods: In this multicenter, retrospective
-
Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect. Thyroid (IF 6.6) Pub Date : 2023-10-01 Amanda Silver Karcioglu,Amr H Abdelhamid Ahmed,Zipei Feng,Marika Russell,David C Shonka,Ayaka Iwata,Maria Cabanillas,Jennifer J Shin,Natalia Kyriazidis,Jong Chul Park,Lori J Wirth,Mark E Zafereo,Gregory W Randolph
-
Equitable Solutions Are Needed for Patients Who Seek Treatment for Thyroid Cancer at Ultra-Low-Volume Hospitals. Thyroid (IF 6.6) Pub Date : 2023-09-28 Cord Sturgeon,Nadine R Caron
-
Response to Yan et al. re: "Could Radioactive Iodine Be a Preferred Therapy for Graves' Hyperthyroidism Patients with Large Goiters? A Viewpoint from China". Thyroid (IF 6.6) Pub Date : 2023-09-28 Douglas S Ross
-
Contralateral Low-to-Intermediate Suspicion Nodule Is Not a Contraindication for Lobectomy in Patients with Papillary Thyroid Carcinoma. Thyroid (IF 6.6) Pub Date : 2023-09-26 Shin Jeong Pak,Douk Kwon,Byung-Chang Kim,Jae Won Cho,Won Woong Kim,Yu-Mi Lee,Tae-Yon Sung,Jung Hwan Baek,Won Gu Kim,Won Bae Kim,Ki-Wook Chung
Background: The optimal extent of surgery for unilateral papillary thyroid carcinoma (PTC) with contralateral nodules remains unclear. This study evaluated the long-term outcomes in a large cohort of patients with unilateral PTC and contralateral low-to-intermediate suspicious nodules who underwent lobectomy. Methods: This retrospective cohort study included patients with unilateral PTC who underwent
-
GlycA as a Novel Biomarker of Systemic Inflammation in Hypothyroidism. Thyroid (IF 6.6) Pub Date : 2023-09-22 Sarah Galvao,Isabela M Bensenor,Michael J Blaha,Steven Jones,Peter P Toth,Raul D Santos,Marcio Bittencourt,Paulo A Lotufo,Patrícia de Fátima Dos Santos Teixeira
Background: GlycA is a novel glycoprotein biomarker of systemic inflammation and cardiovascular risk. Our objective was to assess the levels of GlycA in individuals with hypothyroidism. We also explored whether levothyroxine (LT4)-treated patients had different levels of GlycA, with attention to thyrotropin (TSH) levels. Methods: We performed a cross-sectional analysis, using baseline data from the
-
Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy. Thyroid (IF 6.6) Pub Date : 2023-09-20 Yaru Bao,Daham Kim,Yoon Hee Cho,Cheol Ryong Ku,Jin Sook Yoon,Eun Jig Lee
Background: Graves' disease (GD), one of the most common forms of autoimmune thyroid disorders, is characterized by hyperthyroidism caused by antibodies (Abs) against the extracellular A-subunit of the thyrotropin receptor (TSHR). Various approaches have been used to create mouse models of GD, including transfected fibroblasts and immunization with plasmids or adenoviruses expressing human TSHR A-subunit
-
The Diagnostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-Analysis. Thyroid (IF 6.6) Pub Date : 2023-09-19 Ji-In Bang,Sohyun Park,Keunyong Kim,Youngduk Seo,Ari Chong,Chae Moon Hong,Miyoung Choi,Sang-Woo Lee,So Won Oh
Background: The objective of this study is to evaluate the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in detecting recurrence in patients with differentiated thyroid cancer (DTC) who have negative whole-body scans (WBSs) but elevated serum thyroglobulin (Tg) or thyroglobulin antibody (TgAb) levels. Methods: This systematic review/meta-analysis
-
General Principles for the Safe Performance, Training, and Adoption of Ablation Techniques for Benign Thyroid Nodules: An American Thyroid Association Statement. Thyroid (IF 6.6) Pub Date : 2023-09-14 Catherine F Sinclair,Jung Hwan Baek,Kathleen E Hands,Steven P Hodak,Timothy C Huber,Iram Hussain,Brian Hung-Hin Lang,Julia E Noel,Maria Papaleontiou,Kepal N Patel,Gilles Russ,Jonathon Russell,Stefano Spiezia,Jennifer H Kuo
Background: The primary goal of this interdisciplinary consensus statement is to provide a framework for the safe adoption and implementation of ablation technologies for benign thyroid nodules. Summary: This consensus statement is organized around three key themes: (1) safety of ablation techniques and their implementation, (2) optimal skillset criteria for proceduralists performing ablative procedures
-
The Relationship Between Fetal THRB Genotype and Maternal Thyroid Function. Thyroid (IF 6.6) Pub Date : 2023-09-13 Federico Salas-Lucia,Xiao-Hui Liao,Hanzi Jiang,Alexandra M Dumitrescu,Samuel Refetoff,Joao Anselmo
-
Is There a Role for Levothyroxine Therapy in Euthyroid Patients on Active Surveillance for Papillary Microcarcinoma? Thyroid (IF 6.6) Pub Date : 2023-09-11 R Michael Tuttle
-
Progress in Thyroid Cancer Genomics: A 40-Year Journey. Thyroid (IF 6.6) Pub Date : 2023-09-04 James A Fagin,Yuri E Nikiforov
Background: Very little was known about the molecular pathogenesis of thyroid cancer until the late 1980s. As part of the Centennial celebration of the American Thyroid Association, we review the historical discoveries that contributed to our current understanding of the genetic underpinnings of thyroid cancer. Summary: The pace of discovery was heavily dependent on scientific breakthroughs in nucleic
-
Thyrotropin Screening of Newborns: Before or After 72 Hours of Life? Before Discharge or at Home? Thyroid (IF 6.6) Pub Date : 2023-09-04 Emese Boros,Lionel Marcelis,Guy Van Vliet,Farel Elilie Mawa Ongoth,Claudine Heinrichs,Cécile Brachet
Objective: Until November 2019 in Belgium, dried blood spot (DBS) sampling was performed between 72 and 120 hours of life, when a majority of newborns had already been discharged from the maternity. In November 2019, the policy for newborn screening in South Belgium changed to allow sampling as soon as 48 hours of life, with the objective to accelerate the process and to allow more sampling during
-
Disparities in Initial Thyroid Cancer Care by Hospital Treatment Volume: Analysis of 52,599 Cases in California. Thyroid (IF 6.6) Pub Date : 2023-09-04 Hattie Huston-Paterson,Yifan Mao,Chi-Hong Tseng,Jiyoon Kim,Michael W Yeh,James X Wu
Background: Racially minoritized patients with thyroid cancer are less likely to receive high-quality and guideline-concordant care. Inaccessibility of high-volume centers may contribute to inequalities in thyroid cancer outcomes. This study sought to understand the extent to which access to higher volume thyroid cancer centers is associated with patient outcomes. Methods: We queried linked California
-
Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid (IF 6.6) Pub Date : 2023-09-01 Katleen Van Uytfanghe,Joel Ehrenkranz,David Halsall,Kelly Hoff,Tze Ping Loh,Carole A Spencer,Josef Köhrle
Background: Despite being the most performed laboratory endocrine investigation, the optimum use of thyroid tests (thyrotropin [TSH] and thyroid hormone [TH] measurement) is open to question and the interpretation of the results from these tests can be ambiguous. The American Thyroid Association (ATA) with its expertise support the endeavor of the U.S. Centers for Disease Control (CDC) and the International
-
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy. Thyroid (IF 6.6) Pub Date : 2023-09-01 Jon Wadsley,Gemma Ainsworth,Amy Beth Coulson,Kate Garcez,Laura Moss,Kate Newbold,Kate Farnell,Jayne Swain,Helen Howard,Matthew Beasley,Andrew Weaver,Katie Wood,Jennifer Marshall,Matthew Griffin,Abigail Pascoe,Yong Du,Jan Taprogge,Glenn Flux,Sarah Brown
-
Focusing on the Critical Role of Age and Sex in the Diagnosis of Subclinical Hypothyroidism and Associated Levothyroxine Prescription. Thyroid (IF 6.6) Pub Date : 2023-09-01 Leonidas H Duntas
-
Correction to: The Impact of Age- and Sex-Specific Reference Ranges for Serum Thyrotropin and Free Thyroxine on the Diagnosis of Subclinical Thyroid Dysfunction: A Multicenter Study from Japan by Yamada et al. Thyroid 2023;33(4):428-439; doi: 10.1089/thy.2022.0567. Thyroid (IF 6.6) Pub Date : 2023-08-28
-
The American Thyroid Association 1923-2023: Honoring Our Past, Embracing Our Future. Thyroid (IF 6.6) Pub Date : 2023-08-25 David S Cooper,Peter A Kopp
-
Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease. Thyroid (IF 6.6) Pub Date : 2023-08-23 David Toro-Tobon,Kharisa N Rachmasari,Elizabeth A Bradley,Lilly H Wagner,Andrea A Tooley,Janalee K Stokken,Marius N Stan
Background: Corticosteroid therapy is often employed in thyroid eye disease (TED), but its efficacy is variable. Teprotumumab and tocilizumab have been considered as effective alternatives. This study aims to evaluate their clinical outcomes and safety in patients with steroid-resistant TED. Methods: A retrospective case-control study was conducted between 2018 and 2022 within a national multicenter
-
Maternal Thyroid Function During Pregnancy and Offspring White Matter Microstructure in Early Adulthood: A Prospective Birth Cohort Study. Thyroid (IF 6.6) Pub Date : 2023-08-21 Lassi Björnholm,Olavi Orell,Martta Kerkelä,Ulriika Honka,Sini Laasonen,Tiina Riekki,Heljä-Marja Surcel,Eila Suvanto,Juha Veijola
Background: The fetus is fully dependent on maternal thyroid hormones until mid-gestation and suboptimal maternal thyroid function has been associated with alterations in the neurodevelopment of the offspring. We used maternal free thyroxine (fT4) and thyrotropin (TSH) levels in early gestation to study the association of maternal thyroid function during early pregnancy and offspring brain white matter
-
History of Thyroid Surgery in the Last Century. Thyroid (IF 6.6) Pub Date : 2023-08-18 Lisa A Orloff,Sareh Parangi
Before the 20th century, thyroid surgery was regarded as "horrid butchery" such that no honest and sensible surgeon would ever engage in it. Yet, by the mid-20th century, thyroidectomy had become a respected, life-saving, safe, and increasingly practiced operation. From Kocher to Wells and onward into the 21st century, the evolution of thyroid surgery has continued, enhanced by the integration of endocrinology
-
A Historical Reflection on Scientific Advances in Understanding Thyroid Hormone Action. Thyroid (IF 6.6) Pub Date : 2023-08-18 Gregory A Brent
Background: Thyroid hormone (TH) has actions in every tissue of the body and is essential for normal development, as well as having important actions in the adult. The earliest markers of TH action that were identified and monitored clinically, even before TH could be measured in serum, included oxygen consumption, basal metabolic rate, serum cholesterol, and deep tendon reflex time. Cellular, rodent
-
Letter to the Editor: Could Radioactive Iodine Be a Preferred Therapy for Graves' Hyperthyroidism Patients with Large Goiters? A Viewpoint from China. Thyroid (IF 6.6) Pub Date : 2023-08-18 Shangcheng Yan,Xin Li,Bing Yan
-
Dynamic Screening of Thyroid Function for the Timely Diagnosis of Congenital Hypothyroidism in Very Preterm Infants: A Prospective Multicenter Cohort Study. Thyroid (IF 6.6) Pub Date : 2023-08-11 Ranran Shi,Jie Jiang,Baohong Wang,Fengmin Liu,Xinjian Liu,Dejuan Yang,Zhongliang Li,Haiying He,Xuemei Sun,Qiongyu Liu,Huimin Li,Jinrong He,Jiabi Yu,Ming Zhang,Simmy Reddy,Yonghui Yu,Jiajun Zhao
Background: Preterm infants presented a high prevalence of congenital hypothyroidism (CH), while the optimal screening pattern is still under debate. This study aimed at evaluating the characteristics of thyroid function by conducting weekly screening during the first month of life in very preterm infants (VPIs) to achieve timely diagnosis and treatment of CH. Methods: A prospective cohort study was